Gene-targeted cancer drugs, slow release overcome resistance

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, protein engineering and biomaterials science to improve the efficacy, accuracy and longevity of certain cancer therapies.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Related Links:

In this study, PAMAM G5 modified with cholesteryl chloroformate and alkyl-PEG was applied for co-delivery of doxorubicin (DOX) and plasmid encoding TRAIL into colon cancer cells, in vitro and in vivo. The results showed DOX was efficiently encapsulated in modified carrier (M-PAMAM) with loading level about 90%, and the resulting DOX-loaded M-PAMAM complexed with TRAIL plasmid showed much stronger antitumor effect than M-PAMAM containing DOX or TRAIL plasmid. On the other hand, the obtained results demonstrated that the treatment of mice bearing C26 colon carcinoma with this developed co-delivery system significantly decrea...
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Publication date: Available online 13 October 2019Source: Seminars in Cancer BiologyAuthor(s): Vikram Shaw, Suyash Srivastava, Sanjay K. SrivastavaAbstractThe recent development of high throughput compound screening has allowed drug repurposing to emerge as an effective avenue for discovering novel treatments for cancer. FDA-approved antipsychotic drugs fluspirilene, penfluridol, and pimozide are clinically used for the treatment of psychotic disorders, primarily schizophrenia. These compounds, belong to diphenylbutylpiperidine class of antipsychotic drugs, are the potent inhibitors of dopamine D2 receptor and calcium chan...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 October 2019Source: Materials LettersAuthor(s): Xiaoqian Feng, Wei Xu, Chi Zhang, Shuo Tan, Jian Zhang, Peng Zhang, Yang ZhangAbstractYolk-shell nanostructures haves promising applications in cancer therapy due to their great potential for multi-functions. However, the control over its structure and morphology still remains a big challenge. Herein, yolk-shell Fe3O4@C-Au composite nanostructure has been successfully synthesized with magnetic Fe3O4 nanoparticles encapsulated in hollow carbon shells and Au nanoparticles well dispersed. The yolk-shell structure has a uniform size of ∼8...
Source: Materials Letters - Category: Materials Science Source Type: research
Non-responsive subpopulation of tumor cells, and acquired resistance in initially responsive cells are major challenges for cancer therapy with molecularly-targeted drugs. While point mutations are considered the major contributing factor to acquired resistance, in this study we explored the role of heterogeneity and plasticity of selected human breast cancer cell lines (MDA-MB-231, MDA-MB-468, and AU565) in their initial and adjusted response, respectively, to ruxolitinib, everolimus, and erlotinib. After determination of lethal concentration for 50% cell death (LC50), cells were exposed to selected drugs using three diff...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Li Naturally occurring polyphenols are believed to have beneficial effects in the prevention and treatment of a myriad of disorders due to their anti-inflammatory, antioxidant, antineoplastic, cytotoxic, and immunomodulatory activities documented in a large body of literature. In the era of molecular medicine and targeted therapy, there is a growing interest in characterizing the molecular mechanisms by which polyphenol compounds interact with multiple protein targets and signaling pathways that regulate key cellular processes under both normal and pathological conditions. Numerous studies suggest that natural poly...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionMSI has the potential to become a key predictor for evaluating the degree of malignancy, efficacy and prognosis of tumours. Clinically, MSI patterns will provide more valuable information for clinicians to create optimal individualized treatment strategies based on frameshift peptides vaccines.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Authors: Xu W, Lou Y, Chen W, Kang Y Abstract Effective cancer therapy usually requires the assistance of well-designed drug carriers. In order to increase the drug accumulation to tumor tissue as well as to reduce the side effects of drug carriers, the hybrid drug delivery system (DDS) was developed by integrating folic acid (FA) and a metal-organic framework (MOF). The anticancer drug doxorubicin (DOX) was preloaded into the MOF nanoparticles during the synthesis process of the MOF nanoparticles. After surface modification with FA, the resulting FA/MOF/DOX nanoparticles were capable of serving as a biocompatible ...
Source: Biomedizinische Technik/Biomedical Engineering - Category: Biomedical Engineering Tags: Biomed Tech (Berl) Source Type: research
This article demonstrates the fabrication of versatile nanoformulation by conveniently wrapping the ultrasmall platinum nanoparticles-dispersed over the zinc metal-doped mesoporous silica-based nanocarriers (Zn-MSNs) for not only conveying the drug cargo efficiently but also facilitating the advanced abilities of deep tumor penetration through interacting with adherens junctions and aphotic (dark) synergistic therapeutic effects to combat cancer multidrug resistance.
Source: Chemical Engineering Journal - Category: Chemistry Source Type: research
With the popularization of Next-generation sequencing technology, targeted cancer therapy based on gene mutations has attracted more and more attention. Aberrant activated mitogen-activated protein kinases (MAPK) pathway is considered to play a crucial role in the occurrence and development of various cancers [1]. Various mutations in pathway components including MEK1/2 can cause the aberrant activation of MAPK signaling pathway [2]. As oncogenic mutations, MEK1 mutations were widely observed in many cancers [1,3,4], while trametinib, a MEK1/2 inhibitor, was limited to treat BRAF-mutant melanoma and non-small-cell lung can...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research
Ye Xu Successful cancer therapy requires drugs being precisely delivered to tumors. Nanosized drugs have attracted considerable recent attention, but their toxicity and high immunogenicity are important obstacles hampering their clinical translation. Here we report a novel “cocktail therapy” strategy based on excess natural killer cell-derived exosomes (NKEXOs) in combination with their biomimetic core–shell nanoparticles (NNs) for tumor-targeted therapy. The NNs were self- assembled with a dendrimer core loading therapeutic miRNA and a hydrophilic NKEXOs shell. Their successful fab...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Pharmaceuticals | Science